Expected Moves

Alpek's Q3 2026 earnings release will test the sustainability of its Q2 net income turnaround (EPS of $1.99 vs negative prior quarters). Favorable margins could push the stock to $0.82, while a reversion to chemical spread compression risks $0.60.

Q4 results and forward management guidance will define 2027 capital expenditure plans and margin expectations. A strong 2027 outlook targets $0.95, while conservative guidance drops the stock to $0.68.

Under President Trump's administration, potential trade policy shifts and tariffs on Mexican petrochemical exports pose a structural risk. An exemption or favorable ruling targets $1.05, but the imposition of new tariffs severely dents margins down to $0.75.

Q1 2027 earnings will absorb the impacts of Q1 macro dynamics and finalized CapEx execution. Navigating these headwinds pushes valuation to $0.88, while volume contraction drops shares to $0.62.

With nearly $37B in reported total debt, a mid-year capital structure update or proactive debt refinancing is expected. Successfully clearing maturity walls recovers the stock to $0.78, while a failed syndication tests the 52-week low of $0.45.